Healthcare providers across Canada will soon be able to capture adverse events in the Auxita platform through integration with MyMeds&Me’s pharmacovigilance SaaS platform, Reportum.®
This partnership integrates MyMeds&Me’s validated safety data capture solution into Auxita, enabling healthcare providers, patient support programs and pharmaceutical companies to capture and manage data more efficiently.
MyMeds&Me® is a global organization that provides an established end-to-end pharmacovigilance solution to simplify adverse event and product quality data capture. Its drug safety platform, Reportum, is used by pharmaceutical companies around the world to standardize data capture, streamline downstream processes and provide real-time access to complete, relevant safety information.
“Auxita is pleased to expand our service offering to enhance the management of safety data, captured at source from healthcare providers,” says Matt Cahill, CEO of Auxita. “Through our EMR and EHR-integrated platform, we provide an intuitive and standardized digital process to collect data and manage the flow of information throughout the patient journey. This partnership will offer patient support programs real-time access and enhanced visibility to key safety information.”
“Robust pharmacovigilance relies on a comprehensive body of complete, structured, and timely data. Therefore, it is critical that we make safety reporting really easy and intuitive for both physicians and patient support program staff whether in the office or out in the field” says Dr. Andrew Rut, CEO and founder of MyMeds&Me. “Our partnership with Auxita enables efficient capture of standardized information for our clients so they can accelerate safety insights.”
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.